Orthofix International (OFIX) Receives Daily Media Impact Rating of 0.21
Headlines about Orthofix International (NASDAQ:OFIX) have been trending somewhat positive on Thursday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Orthofix International earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave press coverage about the medical device company an impact score of 46.5099264559027 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news stories that may have effected Accern’s rankings:
- Brokers Issue Forecasts for Orthofix International NV’s FY2020 Earnings (OFIX) (americanbankingnews.com)
- Orthofix International NV (OFIX) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
- Brokerages Anticipate Orthofix International NV (OFIX) Will Announce Quarterly Sales of $107.65 Million (americanbankingnews.com)
- [$$] Orthofix Acquires Spinal Kinetics (finance.yahoo.com)
- Orthofix Announces Agreement to Acquire Spinal Kinetics (finance.yahoo.com)
Shares of Orthofix International stock opened at $59.56 on Thursday. The company has a market capitalization of $1,092.89, a PE ratio of 180.49, a PEG ratio of 3.34 and a beta of 0.24. Orthofix International has a 1 year low of $36.10 and a 1 year high of $61.00.
A number of brokerages have issued reports on OFIX. TheStreet upgraded Orthofix International from a “c+” rating to a “b” rating in a report on Tuesday. BidaskClub upgraded Orthofix International from a “hold” rating to a “buy” rating in a report on Friday, March 16th. Gabelli restated a “buy” rating on shares of Orthofix International in a report on Wednesday, February 28th. SunTrust Banks raised their target price on Orthofix International to $67.00 and gave the stock a “buy” rating in a report on Monday, March 5th. Finally, ValuEngine upgraded Orthofix International from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Orthofix International has a consensus rating of “Buy” and a consensus price target of $57.42.
About Orthofix International
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Receive News & Ratings for Orthofix International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International and related companies with MarketBeat.com's FREE daily email newsletter.